BridgeBio Pharma Inc (BBIO)
30.10
-0.94
(-3.04%)
USD |
NASDAQ |
May 17, 16:00
30.10
0.00 (0.00%)
Pre-Market: 20:00
BridgeBio Pharma Enterprise Value: 6.840B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 6.840B |
| May 16, 2024 | 7.017B |
| May 15, 2024 | 6.817B |
| May 14, 2024 | 6.626B |
| May 13, 2024 | 6.542B |
| May 10, 2024 | 6.654B |
| May 09, 2024 | 6.585B |
| May 08, 2024 | 6.392B |
| May 07, 2024 | 6.409B |
| May 06, 2024 | 6.465B |
| May 03, 2024 | 6.417B |
| May 02, 2024 | 6.400B |
| May 01, 2024 | 6.267B |
| April 30, 2024 | 6.003B |
| April 29, 2024 | 5.975B |
| April 26, 2024 | 5.865B |
| April 25, 2024 | 5.762B |
| April 24, 2024 | 5.893B |
| April 23, 2024 | 5.973B |
| April 22, 2024 | 5.900B |
| April 19, 2024 | 5.838B |
| April 18, 2024 | 5.878B |
| April 17, 2024 | 5.883B |
| April 16, 2024 | 5.932B |
| April 15, 2024 | 6.031B |
| Date | Value |
|---|---|
| April 12, 2024 | 6.229B |
| April 11, 2024 | 6.516B |
| April 10, 2024 | 6.323B |
| April 09, 2024 | 6.529B |
| April 08, 2024 | 6.499B |
| April 05, 2024 | 6.467B |
| April 04, 2024 | 6.476B |
| April 03, 2024 | 6.679B |
| April 02, 2024 | 6.598B |
| April 01, 2024 | 6.819B |
| March 31, 2024 | 6.995B |
| March 28, 2024 | 7.007B |
| March 27, 2024 | 6.996B |
| March 26, 2024 | 6.793B |
| March 25, 2024 | 6.725B |
| March 22, 2024 | 6.760B |
| March 21, 2024 | 6.649B |
| March 20, 2024 | 6.584B |
| March 19, 2024 | 6.548B |
| March 18, 2024 | 6.433B |
| March 15, 2024 | 6.387B |
| March 14, 2024 | 6.348B |
| March 13, 2024 | 6.500B |
| March 12, 2024 | 6.597B |
| March 11, 2024 | 6.642B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.607B
Minimum
Mar 18 2020
10.69B
Maximum
Feb 08 2021
4.886B
Average
3.824B
Median
Enterprise Value Benchmarks
| Pfizer Inc | 219.35B |
| Alnylam Pharmaceuticals Inc | 17.55B |
| Regenxbio Inc | 448.90M |
| ACADIA Pharmaceuticals Inc | 1.973B |
| Biomarin Pharmaceutical Inc | 14.77B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.22M |
| Revenue (Quarterly) | 211.12M |
| Total Expenses (Quarterly) | 207.38M |
| EPS Diluted (Quarterly) | -0.20 |
| Gross Profit Margin (Quarterly) | 99.72% |
| Profit Margin (Quarterly) | -16.68% |
| Earnings Yield | -10.70% |
| Normalized Earnings Yield | -10.38 |